Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity

Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions

Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind™ toxicology services in liver and small intestine. The appointments expand VivoSim's commercial presence across Asia-Pacific, which potentially provides faster access to human-relevant toxicology services for pharmaceutical and biotechnology organizations facing growing pressure to de-risk programs earlier and accelerate timelines.

Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms